| 10.125 -0.335 (-3.2%) | 03-12 14:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.5 | 1-year : | 14.61 |
| Resists | First : | 10.71 | Second : | 12.5 |
| Pivot price | 8.93  |
|||
| Supports | First : | 7.72 | Second : | 5.88 |
| MAs | MA(5) : | 10.1 |
MA(20) : | 8.62 |
| MA(100) : | 5.61 |
MA(250) : | 3.56 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 89.5 |
D(3) : | 90.1 |
| RSI | RSI(14): 74.2 |
|||
| 52-week | High : | 10.71 | Low : | 1.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IMMX ] has closed below upper band by 13.3%. Bollinger Bands are 64.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.66 - 10.7 | 10.7 - 10.73 |
| Low: | 9.77 - 9.81 | 9.81 - 9.86 |
| Close: | 10.38 - 10.45 | 10.45 - 10.51 |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Mon, 09 Mar 2026
Immix Biopharma (NASDAQ:IMMX) Hits New 12-Month High - Should You Buy? - MarketBeat
Mon, 09 Mar 2026
Citizens initiates Immix Biopharma stock coverage with outperform rating - Investing.com
Sat, 07 Mar 2026
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Tue, 03 Mar 2026
Investors get March access to Immix Biopharma at Miami conferences - Stock Titan
Mon, 16 Feb 2026
Analysts Expect Breakeven For Immix Biopharma, Inc. (NASDAQ:IMMX) Before Long - simplywall.st
Fri, 13 Feb 2026
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 22.3 (%) |
| Held by Institutions | 46.8 (%) |
| Shares Short | 3,430 (K) |
| Shares Short P.Month | 2,270 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.5 % |
| Return on Equity (ttm) | -182.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -13.29 |
| PEG Ratio | 0 |
| Price to Book value | 40.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -37.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|